Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-418 in Healthy Female Subjects
NCT03501069Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-418 in Kabuki syndrome and Autism Spectrum Disorder (ASD) (6 cohorts), sponsored by Millennium Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events, Serious Adverse Events and 3 more. Started May 2018; status: terminated.
02
Drugs
TAK-418
03
Conditions
Kabuki syndromeAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03501069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501069.